Navigation Links
Phase 3 trials of two multi-kinase inhibitors against cancer

Sorafenib and stutent multi-kinase inhibitors against cancer is undergoing phase 3 trials// and these two drugs gained more appreciation in this years ASCO (American Society of Clinical Oncology) conference. This drug is gaining interest due to its multiple mechanism of action – known as Multi-kinase inhibitors. These drugs are in trial against different types of cancer and are found to be very effective. This two multi targeted oncology drug candidate is a small molecule named Sorafenib (Bay43-9006) and stutent (SU11248).

Sorafenib is produced by Onyx pharmaceuticals of California collaborating with Bayer pharmaceuticals of Connecticut and Stutent by Pfizer of New York city. Both these drugs are undergoing phase 3 trials.

Results of the study show that Sorafenib in advanced kidney cancer patients taking the drug lived twice as long as that placebo. Gleevec (imatinib) resistant gastrointestinal stromal tumors (GIST) were much less likely to progress in patients taking stutent versus those on placebo.

Both these drug act against tumor and its ability to recruit new blood vessels essential for growth and dissemination via multiple mechanisms. Sorafenib works by inhibiting the RAF/MEK/ERK pathway and, in parallel, impedes angiogenesis by inhibiting vascular endothelial growth factor-2 (VEGF-2) and platelet derived growth factor beta (PDGF- a). Stutent also has dual actions, killing VEGF and PDGF- á and a as well as FLT-3 and C-KIT.

Pfizer is developing more multi-targeted cancer drugs, such as small AG-013736 which has encouraging results in its phase 2 trials in kidney cancer.

Multi-targeted drug has also downsides of having side effects and allow less flexibility. But, so far there was no side effects reported in Sorafenib or stutent.


'"/>




Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Phase II trails of new HIV vaccine to be held in South Africa
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:
(Date:12/2/2008)...ON, Dec. 2 In an open l...sociation of Homes and Services for the Aging (AAH...our ways that the Obama administration can make bo...s to the way America cares for its most vulnerable... Expand the Nation,s Work Force: Create Jobs in ...
(Date:12/2/2008)... Dec. 2 Today a group ...ions, elected officials and other community leader...ds in Detroit/Wayne County to solidify participant...ure and economic successes and challenges play a r...t of the opening session of a three-day discussion...
(Date:12/2/2008)...y be better spent in other areas, experts say , ...ital rapid response teams, created to prevent card...do not seem to work, a new study finds. , "Many...ast decade," said lead researcher Dr. Paul S. Chan...e in Kansas City, Mo. "Earlier studies had shown t...
(Date:12/2/2008)...ound most were as effective, despite editorials ur...lthDay News) -- Brand-name drugs used to treat car... new review of available evidence shows. , Yet ...n by specialists, have urged against substituting ...nterparts. , "We found no evidence that brand-n...
Breaking Medicine News(10 mins):Health News:Think Tank Investigates the Environmental Conditions Surrounding Health Inequities 2Health News:Think Tank Investigates the Environmental Conditions Surrounding Health Inequities 3Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 3Health News:Generic Heart Drugs as Good as Brand-Name Counterparts 2Health News:Generic Heart Drugs as Good as Brand-Name Counterparts 3
...f dust mites in the bedroom can be achieved by rep...ilation, according to a new study.// In “Distribu...in Europe: The European Community Respiratory Heal...icipal Institute of Medical Research, Barcelona, S...
...t death syndrome has been the cause of many infant...baby sleeps on its back. In a bid to investigate t...able, researchers discovered that infants born wit...nes were prone to the risk of SIDS. The study ha...
... a $20 billion pharma firm based in the Netherland...India and hoped to capture a 10 percent share of t...uously exploring opportunities to invest in India.... million per annum," said company president Gerard...
... by Cancer Research UK finds that many women with ...en seem to genuinely forget to take their medicati...ugs. Difficulty in coping with side effects and i...iven as main reasons for quitting the pills. Anoth...
Other Medicine News:Health News:Replacing Old Mattress, Adding Ventilation Reduces Mites 2
(Date:12/1/2008)...st policy , , ROCHESTER, Minn., Dec. 1 /PR...ic finds the use of the drug therapy etanercept in...e inflammation of the liver caused by excessive co... published in the December issue of Gastroenterol... VIDEO ALERT: Additional audio and video resource...
(Date:12/1/2008)...rstCall/ -- Vical Incorporated (Nasdaq: VICL ) a...tone payment from Merck & Co., Inc. based on M...ial of an investigational plasmid DNA (pDNA) cance...,s DNA gene delivery technology and encodes human ... the subject of separate license agreement. , ...
(Date:11/27/2008)...acute lymphoblastic leukemia relapse cases arise f...s , , MEMPHIS, Tenn., Nov. 27 /PRNewswire-U...search Hospital have identified distinctive geneti...te lymphoblastic leukemia (ALL) that cause relapse...ents for ALL relapse in children and, ultimately, ...
(Date:11/25/2008)...wire-USNewswire/ -- Kleinert Kutz and University ....S. hand transplant on Messina, New York resident,...tal Hand Care Center on Monday, November 24. The ...pleted shortly after 9 p.m. in a record nine hours...bin/prnh/20081125/DC48555-a ) , (Photo: http:...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Oracle Healthcare Acquisition Corp Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 18720 1Oracle Healthcare Acquisition Corp Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 18720 2Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday May 14 2008 5202 1FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 5200 1FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 5200 2FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 5200 3ImaRx Schedules Release of First Quarter 2008 Financial Results 5198 1
...007 – Intercell AG (VSE,“ICLL”)...& Co., Inc. on the results of a Phase I study ...rs comparing safety and,immunogenicity of differen...he Staphylococcus aureus vaccine is based on a con...uo;s Antigen Identification,Program (AIP®) and...
...2007 /PRNewswire-FirstCall/ -- A total,of 20 oral ...Schering-Plough,s hepatitis products, including PE... (ribavirin, USP) combination,therapy for chronic ...previr (SCH 503034), the company,s investigational... clinical development, will,be presented by leadin...
Other Medicine Technology:Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 2Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 2Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 4Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 5Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 6Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 7
...ew generation Endoalpha is a centralized O.R. cont...nurse by giving them better control, better inform... protection against obsolescence, as future enhanc...r than the purchase of an entirely new system. End...
Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue.
Radionics' new OmniSight image guided surgery system offers full-featured image guidance while maintaining simplicity in design and use. It provides unparalleled three-dimensional visualization, allo
The StealthStation TRIA has been developed to provide a cost effective, yet highly capable, introduction to your image guided surgery program. The system is available with Medtronic SNT's full suite
Medicine Products: